Ivermectin Safety: Side Effects, Risks, and What Evidence Shows

Ivermectin has been used in humans for nearly four decades and in hundreds of millions of doses worldwide, giving it one of the more thoroughly documented safety profiles of any antiparasitic medicine. This article sets out what the clinical evidence actually shows about its side effects, the rare but serious risks, who should not take it, and how overdose occurs — separating what is well established from what remains uncertain, and correcting some common confusion along the way.

What Ivermectin Is and Why It Was Developed

Ivermectin is derived from avermectin, a compound produced by Streptomyces avermitilis, a bacterium first isolated from soil near a golf course in Japan in the 1970s. It is a fitting reminder that some of medicine's most useful tools have come from the ordinary materials of creation, refined through careful science. Satoshi Ōmura and William Campbell shared the 2015 Nobel Prize in Physiology or Medicine for this discovery, which transformed the treatment of parasitic diseases that had caused blindness and disfigurement across the developing world for generations.

In the United States, oral ivermectin is approved by the FDA under the brand name Stromectol (and as generic tablets, commonly in 3 mg strength, with the total dose calculated by body weight) for two indications: intestinal strongyloidiasis and onchocerciasis, better known as river blindness. Topical formulations are approved for head lice and rosacea. In countries where onchocerciasis and lymphatic filariasis are endemic, ivermectin is distributed in mass campaigns, sometimes in 6 mg or 12 mg tablets, dosed according to weight. It is not approved by the FDA, or by equivalent regulators in the UK, EU, Canada, or Australia, for the prevention or treatment of COVID-19, and it has no approved role in cancer treatment. Readers considering it for anything outside its approved uses should understand that they are outside the evidence base those approvals rest on, and should do so only in conversation with their own physician.

Common Side Effects: What the Data Shows

At approved doses, ivermectin is generally well tolerated. Clinical trials and post-marketing surveillance from decades of use identify a fairly consistent, mostly mild side-effect profile:

• Dizziness and headache
• Nausea, vomiting, diarrhea, or loss of appetite
• Muscle or joint aches
• Mild skin rash or itching
• Transient drowsiness

These effects are typically self-limiting and resolve within a day or two. Large-scale data from the WHO-coordinated Mectizan Donation Program, which has distributed well over a billion doses for onchocerciasis and lymphatic filariasis since 1987, has repeatedly documented this pattern of mild, transient effects in the general treated population, with serious reactions occurring at low rates.

Serious Adverse Reactions and the Overdose Question

The more serious reactions associated with ivermectin are important to understand correctly, because several of them arise not from the drug's direct toxicity but from the body's response to dying parasites.

Patients being treated for onchocerciasis who carry a high burden of microfilariae (the larval worms) can experience what is called a Mazzotti reaction: fever, intense itching, swollen lymph nodes, joint pain, and a drop in blood pressure, occurring as the immune system reacts to the sudden die-off of parasites rather than to ivermectin itself. This is a recognized and monitored risk in endemic-disease treatment programs, not a sign that the drug is inherently dangerous — it is a predictable consequence of successfully clearing a heavy parasitic load, and clinicians manage it accordingly.

A separate and more serious concern applies to individuals co-infected with Loa loa, a filarial parasite found in parts of Central Africa. In people with very high Loa loa microfilarial counts, ivermectin has been associated with rare but severe neurological reactions, including encephalopathy, documented in field studies conducted during African mass drug administration campaigns in the 1990s. This is why pre-treatment screening for Loa loa is standard practice in affected regions before mass dosing.

Regarding overdose: at labeled human doses, ivermectin has a wide margin of safety, and clinical overdose in patients taking correctly formulated, correctly dosed tablets is uncommon. The picture changes considerably when people take ivermectin formulated for livestock, which is far more concentrated and intended to be dosed by animal body weight, not human weight. U.S. poison control centers and the CDC documented a marked rise in ivermectin exposure calls in 2021, with a significant share involving veterinary products; reported effects at high or veterinary-strength exposures included vomiting, diarrhea, low blood pressure, confusion, seizures, and in a small number of cases, coma. This is a genuine and avoidable risk, and it underscores a basic principle of stewardship over one's own health: use only human-labeled medication, at a dose confirmed with a pharmacist or physician, never an animal formulation.

Who Should Avoid Ivermectin

Ivermectin is contraindicated or requires caution in several situations:

• Known hypersensitivity to ivermectin or any component of the formulation, including prior allergic reaction (rash, hives, swelling of the face or throat, or in rare cases anaphylaxis)
• Young children under roughly 15 kg (about 33 lbs), for whom safety data are limited
• Pregnant women, where data are limited and the drug should be used only if a physician judges the benefit clearly outweighs the uncertainty; unnecessary exposure during pregnancy should be avoided as a matter of basic caution toward the unborn child
• Breastfeeding mothers, since ivermectin passes into breast milk in small amounts
• Patients with significant liver impairment, since the drug is metabolized hepatically
• Residents of, or travelers with recent exposure to, Loa loa–endemic regions, who should be screened before mass treatment
• Patients on other CNS-active medications or high-dose warfarin, where ivermectin may increase sedation or bleeding risk respectively, warranting monitoring

None of this means ivermectin is a dangerous drug in the hands of a physician who knows a patient's history. It means what is true of essentially every effective medicine: it needs to be matched to the person taking it, which is precisely the judgment a treating doctor is positioned to make.

Long-Term Safety: Decades of Real-World Data

Because ivermectin is administered annually, sometimes for many consecutive years, to tens of millions of people in onchocerciasis and lymphatic filariasis control programs across Africa and Latin America, there is an unusually long track record to draw on. Post-marketing surveillance and epidemiological follow-up from these programs, tracked by the World Health Organization and academic partners over more than three decades, have not identified evidence of cumulative organ toxicity, carcinogenicity, or delayed-onset harm from repeated annual dosing. This is one of the better-documented long-term safety records among antiparasitic drugs, precisely because it has been used at scale, in real populations, for a very long time — a point worth weighing against unverified claims of hidden long-term harm that circulate online and are not supported by the surveillance data collected from these programs.

That said, "long-term safety" in this context refers to intermittent annual dosing for parasitic disease, not daily or repeated dosing for unapproved purposes. Chronic, off-label use at frequencies or doses outside the studied pattern has not been systematically studied, and caution is warranted where evidence does not exist.

A Note on Dosing and Off-Label Use

Confusion between tablet strengths — 3 mg (the standard U.S. Stromectol strength), 6 mg, and 12 mg (both used in weight-based dosing in various countries) — has led some people to misjudge how much they are taking. The tablet strength alone does not tell you the correct dose; the correct total dose depends on body weight and indication, which is why prescribing is weight-based and why self-dosing from tablets obtained outside a pharmacy carries real risk of error.

During the COVID-19 pandemic, ivermectin drew wide public interest as a potential treatment. Since then, well-conducted randomized controlled trials — including the NIH-funded ACTIV-6 trial and the Brazilian TOGETHER trial, both published in peer-reviewed journals in 2022–2023 — found no meaningful reduction in COVID-19 hospitalization, recovery time, or death among outpatients treated with ivermectin compared with placebo. This is worth stating plainly, not to dismiss anyone's earlier hopes, but because accurate information is the foundation of informed consent: patients deserve to know what the best available trials actually found so they can make decisions with their own doctor, rather than on the basis of incomplete information.

Key takeaway: Used at approved doses for its approved indications and under a physician's guidance, ivermectin has one of the longer, better-documented safety records of any antiparasitic drug, but it is not risk-free, is not approved for COVID-19, and should never be taken in veterinary formulations or without confirming the correct human dose.